Robert L Avery Selected Research

Ranibizumab (Lucentis)

8/2019	Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab.
10/2017	SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
2/2016	Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52).
1/2016	Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
1/2016	Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
12/2014	Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.
10/2013	Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.
1/2012	A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.
6/2011	Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
10/2008	Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert L Avery Research Topics

Disease

12	Macular Degeneration (Age-Related Maculopathy) 01/2022 - 03/2006
9	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 10/2006
9	Macular Edema 10/2017 - 03/2006
4	Retinal Vein Occlusion 10/2017 - 04/2007
3	Choroidal Neovascularization 08/2019 - 03/2006
3	Endophthalmitis (Ophthalmia) 12/2014 - 11/2006
2	Retinopathy of Prematurity (Retrolental Fibroplasia) 07/2020 - 02/2012
2	Blindness (Hysterical Blindness) 07/2020 - 01/2018
2	Inflammation (Inflammations) 04/2019 - 02/2007
2	Diabetes Mellitus 04/2017 - 10/2006
2	Epiretinal Membrane (Epiretinal Membranes) 04/2017 - 09/2007
2	Edema (Dropsy) 12/2016 - 06/2011
2	Retinal Perforations 06/2015 - 09/2011
2	Retinal Detachment (Retinal Detachments) 01/2015 - 06/2004
2	Hemorrhage 06/2011 - 02/2007
2	Retinal Hemorrhage 10/2008 - 02/2007
1	Geographic Atrophy 01/2022
1	Ischemia 01/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Hyperglycemia 01/2019
1	Hypertension (High Blood Pressure) 12/2016
1	Stroke (Strokes) 01/2016
1	Myocardial Infarction 01/2016
1	Vascular Diseases (Vascular Disease) 01/2016
1	Open-Angle Glaucoma (Glaucoma, Open Angle) 04/2015
1	Ocular Hypertension (Glaucoma, Suspect) 04/2015
1	Infections 12/2014
1	Retinal Diseases 06/2014
1	Pain (Aches) 11/2013
1	Proliferative Vitreoretinopathy 09/2007
1	Papilledema 02/2007
1	Brain Edema (Cerebral Edema) 02/2007
1	Pathologic Neovascularization 11/2006
1	Uveitis 11/2006
1	Anterior Uveitis 09/2006
1	Hyperoxia 06/2004

Drug/Important Bio-Agent (IBA)

12	Bevacizumab (Avastin)FDA Link 10/2017 - 03/2006
11	Ranibizumab (Lucentis)FDA Link 08/2019 - 11/2006
8	Retinaldehyde (Retinal)IBA 01/2022 - 10/2006
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2020 - 11/2006
5	afliberceptIBA 08/2019 - 12/2014
3	Fluorescein (Funduscein)FDA LinkGeneric 10/2013 - 10/2006
3	Biological ProductsIBA 10/2008 - 03/2006
2	paryleneIBA 12/2021 - 01/2018
2	microplasminIBA 04/2017 - 06/2015
2	Pharmaceutical PreparationsIBA 10/2013 - 02/2012
2	VimentinIBA 09/2007 - 06/2004
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2019
1	CytokinesIBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 01/2019
1	Retinal Pigments (Pigments, Visual)IBA 01/2018
1	LipidsIBA 12/2016
1	hydroxide ionIBA 04/2015
1	GlucocorticoidsIBA 04/2015
1	MucinsIBA 04/2015
1	SteroidsIBA 04/2015
1	Aerosolized Particles and DropletsIBA 12/2014
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2014
1	AntibodiesIBA 09/2007
1	Glial Fibrillary Acidic ProteinIBA 09/2007
1	Laminin (Merosin)IBA 09/2007
1	Neurofilament ProteinsIBA 09/2007
1	Bradykinin Receptors (Bradykinin Receptor)IBA 02/2007
1	PrekallikreinIBA 02/2007
1	Kallikreins (Kallikrein)IBA 02/2007
1	Proteins (Proteins, Gene)FDA Link 02/2007
1	Complement C1 (Complement 1)IBA 02/2007
1	ProteomeIBA 02/2007
1	Carbonic Anhydrase IIBA 02/2007
1	Neutralizing AntibodiesIBA 02/2007
1	Intermediate Filament ProteinsIBA 06/2004
1	Oxygen (Dioxygen)IBA 06/2004

Therapy/Procedure

3	Vitrectomy 04/2019 - 09/2007
3	Intravitreal Injections 04/2017 - 09/2006
3	Therapeutics 01/2016 - 06/2004
3	Injections 01/2016 - 10/2008
2	Traction 04/2017 - 06/2015
1	Glycemic Control 01/2019
1	Lasers (Laser) 12/2016
1	Light Coagulation 12/2016
1	Photochemotherapy (Photodynamic Therapy) 01/2012
1	Endotamponade 09/2011
1	Aftercare (After-Treatment) 06/2011